GoAI
Get started
Beijing Biostar Pharms Co Ltd logo

Beijing Biostar Pharms Co Ltd

2563.HK

HKSEHealthcareBiotechnology

Open in GoAI

Latest quote

HK$3.50

−HK$0.01 · -0.29%

Aug 21, 2:50 PM HKT

2563.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Beijing Biostar Pharmaceuticals Co. Ltd. primarily focuses on developing innovative therapies for tumors. The company is dedicated to creating novel anti-cancer drugs, each secured by independent intellectual property rights. A prominent product in its portfolio is the Utidelone injection, a next-generation microtubule inhibitor produced through a unique microbial fermentation process. This enterprise was co-founded by Li Tang and Rong Guo Qiu on July 11, 2002, and operates from its headquarters in Beijing, China.

Industry
Biotechnology
Sector
Healthcare
Headquarters
CN
CEO
Rongguo Qiu
Listed since
Oct 31, 2024
Employees
134

Market position

Volume
17.4K
1.26× average
Average volume
13.8K
Average daily volume
Market cap
843.61M HKD
Beta
-0.17
Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.28B HKD
P/E (TTM)
-8.05×
P/B (TTM)
1.72×
P/S (TTM)
21.13×
EV / EBITDA
-9.15×
Earnings yield
-7.98%
Free cash flow yield
-9.78%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
92.12%
Operating margin
-403.10%
Net margin
-394.42%
Return on equity
-19.24%
Return on assets
-16.55%
Return on invested capital
-19.28%

Financial health

Debt / equity
0×
Current ratio
8.33×
Altman Z-score
2.35
Piotroski F-score
1 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends165%-117%-399%-680%Gross margin, FY2021: 94.13%Gross margin, FY2022: 72.76%Gross margin, FY2023: 70.27%Gross margin, FY2024: 80.20%Gross margin, FY2025: 92.19%Operating margin, FY2021: -385.46%Operating margin, FY2022: -609.81%Operating margin, FY2023: -327.12%Operating margin, FY2024: -236.63%Operating margin, FY2025: -407.86%Net margin, FY2021: -391.40%Net margin, FY2022: -489.06%Net margin, FY2023: -284.60%Net margin, FY2024: -200.06%Net margin, FY2025: -384.03%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 94.13%. Gross margin FY2022 72.76%. Gross margin FY2023 70.27%. Gross margin FY2024 80.20%. Gross margin FY2025 92.19%. Operating margin FY2021 -385.46%. Operating margin FY2022 -609.81%. Operating margin FY2023 -327.12%. Operating margin FY2024 -236.63%. Operating margin FY2025 -407.86%. Net margin FY2021 -391.40%. Net margin FY2022 -489.06%. Net margin FY2023 -284.60%. Net margin FY2024 -200.06%. Net margin FY2025 -384.03%.

Income trends

Revenue

37.12M HKD-52.36%

Operating income

−151.39M HKD+17.89%

Net income

−142.54M HKD+8.56%
Income trends across reported periods159.2M HKD−50.62M HKD−260.43M HKD−470.25M HKDRevenue, FY2021: 106.74M HKDRevenue, FY2022: 37.38M HKDRevenue, FY2023: 73.75M HKDRevenue, FY2024: 77.92M HKDRevenue, FY2025: 37.12M HKDOperating income, FY2021: −411.45M HKDOperating income, FY2022: −227.94M HKDOperating income, FY2023: −241.26M HKDOperating income, FY2024: −184.38M HKDOperating income, FY2025: −151.39M HKDNet income, FY2021: −417.79M HKDNet income, FY2022: −182.81M HKDNet income, FY2023: −209.9M HKDNet income, FY2024: −155.89M HKDNet income, FY2025: −142.54M HKDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 106.74M HKD. Revenue FY2022 37.38M HKD. Revenue FY2023 73.75M HKD. Revenue FY2024 77.92M HKD. Revenue FY2025 37.12M HKD. Operating income FY2021 −411.45M HKD. Operating income FY2022 −227.94M HKD. Operating income FY2023 −241.26M HKD. Operating income FY2024 −184.38M HKD. Operating income FY2025 −151.39M HKD. Net income FY2021 −417.79M HKD. Net income FY2022 −182.81M HKD. Net income FY2023 −209.9M HKD. Net income FY2024 −155.89M HKD. Net income FY2025 −142.54M HKD.
Metric (HKD)FY2025FY2024FY2023FY2022FY2021
Revenue37.12M HKD77.92M HKD73.75M HKD37.38M HKD106.74M HKD
Cost of goods sold2.9M HKD15.43M HKD21.93M HKD10.18M HKD6.26M HKD
Gross profit34.22M HKD62.49M HKD51.83M HKD27.2M HKD100.48M HKD
Research and development92.33M HKD123.71M HKD140.05M HKD70.12M HKD139.78M HKD
Selling, general, and administrative42.54M HKD44.5M HKD154.17M HKD116.37M HKD402.18M HKD
Operating expenses183.68M HKD218.02M HKD293.09M HKD255.14M HKD511.93M HKD
Interest income5.1M HKD5.17M HKD14.54M HKD3.81M HKD—
Interest expense102.82K HKD119.25K HKD63.09K HKD80.86K HKD—
Depreciation and amortization11.52M HKD10.63M HKD11.76M HKD11.96M HKD11.55M HKD
Operating income−151.39M HKD−184.38M HKD−241.26M HKD−227.94M HKD−411.45M HKD
Net income−142.54M HKD−155.89M HKD−209.9M HKD−182.81M HKD−417.79M HKD

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
-0.39
FY2025
Latest fiscal-year revenue
37.12M HKD
FY2025 · -52.36% year over year

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend-0.31-0.63-0.95-1.27FY21FY22FY23FY24FY25

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend113.71M85.86M58.01M30.16MFY21FY22FY23FY24FY25

2563.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.4

-4.08%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.30

-3.94%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$221.8

-2.72%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.54

-4.82%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.14

-5.86%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$100.5

-1.86%

Continue in GoAI

Research 2563.HK

research.disclaimer